33.44 - 34.57
31.40 - 61.90
7.61M / 5.95M (Avg.)
-152.73 | -0.22
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
15.54%
Revenue growth above 1.5x MDB's 6.23%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
13.47%
Gross profit growth above 1.5x MDB's 5.92%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
-9.37%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-9.37%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-6.24%
Negative net income growth while MDB stands at 15.58%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-6.25%
Negative EPS growth while MDB is at 16.80%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-6.25%
Negative diluted EPS growth while MDB is at 16.80%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.58%
Negative OCF growth while MDB is at 154.80%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-11.88%
Negative FCF growth while MDB is at 149.24%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-100.00%
Inventory is declining while MDB stands at 8.13%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-100.00%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
100.00%
Positive BV/share change while MDB is negative. John Neff sees a clear edge over a competitor losing equity.
-100.00%
We’re deleveraging while MDB stands at 27.12%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
16.60%
R&D growth drastically higher vs. MDB's 15.81%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
10.50%
SG&A growth well above MDB's 0.26%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.